Inhibitex, Inc. Initiates Phase II Clinical Trial of FV-100 for the Treatment of Shingles

ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on developing products to treat infectious diseases, today announced that it has initiated a Phase II clinical trial with FV-100, its oral antiviral compound in clinical development for the treatment of herpes zoster (shingles).
MORE ON THIS TOPIC